Companies in #Regenerative Medicine

Celularity is a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and regenerative-medicine products, including the Cenplacel-L point-of-care cellular therapeutic being deployed in regenerative-medicine programs and a portfolio of natural-killer (NK) and T-cell oncology candidates. The company received a Nasdaq notice in May 2026 for delayed filing of its Q1 2026 Form 10-Q and is operating under a 60-day cure-plan window from that notice. Celularity completed a $30M NexGel biomaterials out-license in June 2026 alongside new product-availability partnerships in regenerative medicine.

CollPlant Biotechnologies is a regenerative and aesthetic medicine company developing proprietary recombinant human Type I collagen (rhCollagen) produced in genetically engineered tobacco plants. Its portfolio spans a regenerative dermal filler (VergenixFG/STR), a 3D-bioprinted regenerative soft-tissue matrix, and a rhCollagen-based BioInk for 3D printing of tissues and organs. In June 2026 the company closed a $2.6M registered direct offering of ordinary shares and warrants with H.C. Wainwright as placement agent, with the press release flagging that the proceeds are intended to support ongoing R&D and the evaluation of strategic combinations.

Humacyte is a clinical-stage biotechnology company developing a pipeline of bioengineered human tissues and blood vessels using its proprietary LifePod platform and other regenerative-medicine manufacturing technologies. The lead product, ATEV (Acellular Tissue Engineered Vessel), is a first-in-class bioengineered blood vessel that has shown superiority in female dialysis-access patients in the V012 Phase 3 study (data June 2026), with a supplemental BLA filing planned in H2 2026. The company completed a 47.6M-share underwritten public offering in June 2026.

Satellos Bioscience is a clinical-stage biotechnology company developing novel small-molecule therapies to treat degenerative muscle diseases, with lead candidate SAT-3247 in Phase 2 development for Duchenne muscular dystrophy. The company reported six-month interim data from the TRAILHEAD study in July 2026 showing reduced muscle-fat fraction and improved biomarker signals, and received FDA Fast Track designation for SAT-3247 in June 2026. Satellos is dual-listed on Nasdaq and the TSX and reported cash and equivalents of approximately Cdn $97.5 million as of Q1 2026 with cash runway through 2027.

UniXell Biotechnology Co., Ltd. is a Shanghai-based cell therapy company developing allogeneic induced pluripotent stem cell (iPSC)-derived therapies for neurological disorders. Its lead program UX-DA003, an allogeneic iPSC-derived midbrain dopaminergic progenitor cell therapy, secured FDA IND clearance in June 2026 paired with a parallel NMPA clearance — the first Chinese iPSC Parkinson's program to clear both agencies.